Kisspeptin protocol: Frequently asked questions

Transient nausea occurs in 15–20% of participants during the first 30–60 minutes of intravenous infusion and typically resolves without intervention. Slowing the infusion rate by 25–50% during the initial phase reduces incidence without compromising LH response. Subcutaneous injection site reactions. Redness, swelling, mild pain. Occur in approximately 10% of twice-daily protocols. Rotating injection sites (abdomen, thighs, upper arms) and applying ice immediately post-injection minimizes local inflammation. Persistent severe reactions warrant switching to intravenous delivery.

Extend the stimulation phase for an additional 3–5 days while continuing kisspeptin infusions at the same dose. Follicular development in PCOS is inherently slower than in ovulatory women because of baseline androgen excess and insulin resistance. A 14-day stimulation window is within the physiological range. If follicles remain below 14mm after 14 days, the protocol is discontinued and metabolic optimization (metformin, inositol supplementation) is prioritized before attempting another cycle. Persistent non-response suggests severe insulin resistance or hyperandrogenemia that must be addressed before reproductive interventions.

Withhold the ovulation trigger and cancel the cycle if three or more follicles exceed 14mm diameter. The primary safety advantage of the pcos researchers kisspeptin protocol over exogenous gonadotropins is its low multiple follicle rate. 90% of responders develop a single dominant follicle. When multiple follicles mature, it indicates either excessive dose or an atypical hyperresponsive phenotype. Research protocols define cancellation thresholds at ≥3 mature follicles to prevent high-order multiple pregnancy risk. The patient is advised to use barrier contraception until the follicles regress.

Continue through week 8 before adjusting dose. LH pulsatility restoration precedes subjective symptom relief by 2–4 weeks in most clinical data. Request mid-protocol LH testing (ideally serial samples taken every 10 minutes over 2 hours to capture pulsatile secretion). If LH pulsatility hasn't improved by week 6, the issue is likely peptide stability (storage failure) or underdosing. Increase to 2 nmol/kg per injection or shift from twice-weekly to three times weekly before abandoning the protocol.

If you miss a dose by fewer than 24 hours, administer as soon as you remember and continue your regular schedule. If more than 24 hours have passed, skip the missed dose and resume on your next scheduled date. Do not double-dose. Missing 2+ consecutive doses disrupts GnRH pulsatility patterns you've established, which may cause temporary return of vasomotor symptoms before the next injection restores signalling. Consistency matters more than total weekly dose.

Transient symptom exacerbation during week 1–2 occurs in approximately 12% of women starting kisspeptin therapy and represents paradoxical hypothalamic activation before pulsatility stabilises. The initial GnRH surge can trigger LH spikes that temporarily worsen vasomotor symptoms. This resolves by week 3 in clinical data. If symptoms worsen beyond week 3, check peptide storage integrity and consider reducing dose to 1 nmol/kg before escalating back to 1.5–2 nmol/kg at week 4.

Mild erythema or subcutaneous nodules at injection sites occur in approximately 15% of users and typically resolve within 48 hours. This is a localised inflammatory response to the peptide itself, not contamination. Rotate injection sites consistently. Use a minimum 2 cm distance from prior injection points. If bruising persists, you're likely hitting small capillaries during injection. Inject slower (5–10 seconds per 0.1 mL) and ensure the needle enters at a 45-degree angle into pinched subcutaneous fat, not perpendicular into muscle.

If you miss a dose by fewer than 12 hours, administer it as soon as you remember and continue the regular schedule. If more than 12 hours have passed, skip the missed dose and resume at the next scheduled time. Do not double-dose. For protocols targeting hormonal restoration (e.g., hypothalamic amenorrhea), missing doses delays the cumulative effect on GnRH pulsatility but doesn't require restarting the protocol. For acute social anxiety applications, missing a single intranasal oxytocin dose simply means the cortisol-dampening effect won't be present for that day's social interactions.

Yes. Administer oxytocin 20–30 minutes before kisspeptin for optimal synergy. Oxytocin requires approximately 20 minutes to reduce cortisol levels and modulate HPA axis activity after intranasal administration. If kisspeptin is given first, GnRH neurons are stimulated while cortisol is still elevated, which attenuates the LH response through glucocorticoid receptor-mediated suppression of GnRH pulse amplitude. The Imperial College London trial that demonstrated 41% greater LH secretion used this exact sequence. Oxytocin pretreatment followed by kisspeptin 30 minutes later.

Discard it immediately. Do not inject cloudy or particulate peptide solutions. Cloudiness indicates bacterial contamination, protein aggregation, or improper reconstitution. Properly reconstituted oxytocin and kisspeptin should be completely clear and colorless. If cloudiness appears after storage, it suggests either temperature excursion above 8°C (causing protein denaturation) or contamination during withdrawal. Bacterial contamination can cause severe injection site reactions and systemic infection, while aggregated proteins lose bioactivity and may trigger immune responses.

Reduce the dose to 1.0–1.25mg and administer it with a small, low-fat meal 30 minutes prior. PT-141's nausea is mediated by melanocortin receptor activation in the area postrema (the brain's chemoreceptor trigger zone), and it's dose-dependent. Some researchers pretreat with 12.5–25mg meclizine (an antihistamine with antiemetic properties) 60 minutes before PT-141 injection, which blunts nausea without interfering with MC4R signaling. If nausea persists below 1mg, PT-141 may not be the right peptide for your protocol. Individual MC4R density and chemoreceptor sensitivity vary widely.

PT-141 shows no evidence of tachyphylaxis (tolerance) in Phase III trials spanning 24 weeks of intermittent use (dosing 2–3 times per week), but daily use hasn't been studied and may reduce efficacy through MC4R desensitization. Kisspeptin's long-term use is undefined in humans. Pulsatile protocols maintained for weeks show sustained LH responsiveness, but there's no data on months-long continuous administration. If you're considering extended use, rotate peptides or cycle kisspeptin in 4–6 week blocks to prevent receptor adaptation. Long-term kisspeptin use without medical supervision risks disrupting natural GnRH pulsatility, which could paradoxically suppress reproductive function.

Verify peptide purity and reconstitution first. Degraded or improperly stored kisspeptin loses bioactivity rapidly, and you won't see an LH response if the peptide isn't structurally intact. If storage and handling are correct, consider that continuous or overly frequent dosing desensitizes GPR54 receptors; kisspeptin must be dosed in discrete pulses spaced at least 90 minutes apart. Blood work timing also matters. LH peaks 30–60 minutes post-injection, so testing at 2 hours will miss the pulse entirely. Finally, chronic GnRH agonist or androgen use can suppress hypothalamic responsiveness; kisspeptin won't override long-term receptor downregulation from exogenous testosterone or HCG.